> ## Content Index
> Fetch the complete content index at: https://bioweek.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Gilead Is Buying Oral IL-23 Before Its Peptide Has Shown It Works
- URL: https://bioweek.com/gilead-is-buying-oral-il-23-before-its-peptide-has-shown-it-works/
- Published: 2026-10-25T06:04:47.000Z
- Updated: 2026-10-25T06:04:47.000Z
- Description: Gilead Sciences is paying $1.275 billion upfront for an oral IL-23 receptor drug with no efficacy data, staking a claim on an all-oral IBD franchise built around its own emvistegrast.
- Author: BioWeek
- Tags: Markets, Pipeline

Gilead Sciences [announced](https://www.gilead.com/news/news-details/2026/gilead-to-acquire-investigational-oral-il-23r-inhibitor-hcxt-2001-strengthening-its-inflammation-pipeline-in-ibd?ref=bioweek.com) a definitive agreement on October 22, 2026 to acquire an oral IL-23 receptor inhibitor program, including lead asset HCXT-2001, from privately held PepStar Therapeutics for $1.275 billion in upfront cash. The target is one of the best-validated in inflammatory bowel disease. The molecule has yet to generate a single efficacy datapoint, and Gilead is paying late-stage money for it anyway.

The deal is expected to close in the fourth quarter of 2026, subject to customary conditions, and Gilead said it should reduce GAAP and non-GAAP EPS by roughly $0.79 to $0.83 in that quarter, according to the same [release](https://www.gilead.com/news/news-details/2026/gilead-to-acquire-investigational-oral-il-23r-inhibitor-hcxt-2001-strengthening-its-inflammation-pipeline-in-ibd?ref=bioweek.com). That is a real earnings hit for a Phase 1 asset. The bet is that a clinically validated pathway, plus an oral format, is worth buying before the peptide has treated anyone.

### A validated receptor, an unproven pill

Gilead describes HCXT-2001 as an investigational oral macrocyclic peptide inhibitor of the IL-23 receptor with an extended half-life, calling IL-23R clinically validated in immune-mediated inflammatory diseases including IBD, with potential use in psoriasis. It also [said](https://www.gilead.com/news/news-details/2026/gilead-to-acquire-investigational-oral-il-23r-inhibitor-hcxt-2001-strengthening-its-inflammation-pipeline-in-ibd?ref=bioweek.com) the drug's safety and efficacy have not been established and that it is not approved by any regulator, a disclaimer carrying a lot of weight next to a $1.275 billion check.

The only disclosed human [study](https://clinicaltrials.gov/study/NCT07792928?ref=bioweek.com) is a Phase 1 single-dose, randomized, double-blind, placebo-controlled trial in healthy adults. It is designed to measure safety, tolerability, pharmacokinetics, and immunogenicity in about 40 participants. The listed condition is psoriasis, the sponsor is Shanghai Peptidstar Therapeutics, the start date is October 14, 2026, the completion date is November 10, 2026, and the status is not yet recruiting. There is no induction endpoint, no mucosal healing readout, and no ulcerative colitis or Crohn's cohort in that listing. A validated target does not make a validated molecule, and this one has not yet been asked the question that matters in IBD.

### The oral IL-23 field is already occupied

Gilead is not walking into an empty category. Johnson & Johnson's Icotyde (icotrokinra), a targeted oral IL-23 receptor peptide, is already FDA [approved](https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide?ref=bioweek.com) as a first-line systemic treatment for plaque psoriasis. Injectable IL-23 antibodies still dominate IBD practice. A day after Gilead's deal news, AbbVie [announced](https://news.abbvie.com/2026-10-23-U-S-FDA-Approves-Subcutaneous-Induction-Regimen-for-AbbVies-SKYRIZI-R-risankizumab-rzaa-for-Adults-With-Moderately-to-Severely-Active-Crohns-Disease?ref=bioweek.com) FDA approval of a subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) in moderately to severely active Crohn's disease. The antibody class is still expanding how patients get dosed. An oral IL-23R peptide has a convenience argument. It does not yet have an IBD efficacy argument, and Gilead just paid as if the argument will arrive.

PepStar founder and chief executive Haibing Guo called the transaction a major milestone, citing a proprietary oral peptide platform and what the team accomplished in three years, according to Gilead's [release](https://www.gilead.com/news/news-details/2026/gilead-to-acquire-investigational-oral-il-23r-inhibitor-hcxt-2001-strengthening-its-inflammation-pipeline-in-ibd?ref=bioweek.com). Speed and platform optionality are part of the pitch. Neither substitutes for a controlled IBD readout.

### The real product is a two-pill IBD stack

Chief Medical Officer Dietmar Berger [said](https://www.gilead.com/news/news-details/2026/gilead-to-acquire-investigational-oral-il-23r-inhibitor-hcxt-2001-strengthening-its-inflammation-pipeline-in-ibd?ref=bioweek.com) HCXT-2001 "adds a potentially differentiated oral approach to our growing inflammation pipeline" and that Gilead sees potential for the asset "alone or in combination, including with emvistegrast, as a daily oral treatment for people living with IBD." That sentence is the deal: Gilead is buying the missing oral half of a combination thesis.

Emvistegrast (GS-1427) is Gilead's investigational oral alpha-4-beta-7 integrin inhibitor, another clinically validated IBD pathway. In the Phase 2 SWIFT study in ulcerative colitis, a 12-week placebo-controlled induction phase showed clinical response in 66% (39/59) of emvistegrast patients versus 37% (22/60) on placebo (nominal p<0.001), clinical remission in 31% (18/59) versus 8% (5/60), histologic endoscopic mucosal improvement in 25% versus 10%, and mucosal healing in 24% versus 10%, according to Gilead's [statement](https://www.gilead.com/company/company-statements/2026/phase-2-swift-study-of-emvistegrast-a-potential-differentiated-once-daily-oral-treatment-meets-primary-endpoint-in-ulcerative-colitis?ref=bioweek.com). Gilead plans to start a Phase 3 monotherapy study in 2027 and frames emvistegrast as a potential backbone for future combinations.

That is a more mature asset than HCXT-2001, and it is still not approved. Pairing it with an oral IL-23R inhibitor is a coherent franchise idea: two validated IBD mechanisms, both in a pill, no infusion chair. Coherence is not evidence. Combination use of HCXT-2001 and emvistegrast has not been tested in the disclosed data, and HCXT-2001 has not been tested for efficacy at all.

### Cash now, proof later

The tension in this transaction is simple. IL-23 and alpha-4-beta-7 are proven IBD targets. Icotyde shows that an oral IL-23 receptor peptide can clear a regulator, at least in psoriasis. SKYRIZI's new Crohn's induction option shows the injectable IL-23 franchise is still moving. Gilead is trying to assemble an all-oral IBD stack before either of its own pieces is on the market, writing a $1.275 billion upfront check for a peptide whose human program, as listed, is a roughly 40-person single-dose healthy-volunteer [study](https://clinicaltrials.gov/study/NCT07792928?ref=bioweek.com).

If HCXT-2001 behaves like the class Gilead is buying into, the EPS hit of $0.79 to $0.83 in the fourth quarter of 2026 will look like entry tuition for a franchise. If it does not, Gilead will have paid Phase 3 prices for a molecule that never left Phase 1\. Validated biology got this deal done. The molecule still has to earn it.